Insights from a rare myeloproliferative neoplasm with coexisting
BCR-ABL1 fusion gene, CALR and TET2 mutations treated with nilotinib and
ruxolitinib
Abstract
Myeloproliferative neoplasms (MPNs) with concurrent BCR-ABL1 fusion gene
and CALR mutation are especially rare.We report a patient with
coexisting BCR-ABL1 fusion gene, CALR and TET2 mutations who was treated
with the combination of the second-generation TKI nilotinib and
JAK1/JAK2 inhibitor ruxolitinib.
